PF 4455242

Drug Profile

PF 4455242

Alternative Names: PF-04455242

Latest Information Update: 29 Sep 2010

Price : $50

At a glance

  • Originator Pfizer
  • Class Neuropsychotherapeutics
  • Mechanism of Action Opioid kappa receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Bipolar depression

Most Recent Events

  • 27 Sep 2010 Discontinued - Phase-I for Bipolar depression in USA (PO)
  • 30 Apr 2009 Phase-I clinical trials in Bipolar depression in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top